Dr. Reddy's Laboratories has released lamotrigine extended-release tablets, an anti-seizure medication.


Dr. Reddy's Laboratories, lamotrigine extended-release tablets, Lamictal XR, generic version, GlaxoSmithKline, anti-seizure medication, epileptic seizures








































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Dr. Reddy's launches generic version of Lamictal XR

June 27th, 2013

HYDERABAD, India – Dr. Reddy's Laboratories has released lamotrigine extended-release tablets, an anti-seizure medication.

The India-based drug maker said Wednesday that its lamotrigine product is a therapeutically equivalent generic version of GlaxoSmithKline's Lamictal XR tablets.

Dr. Reddy's lamotrigine XR tablets come in dosages of 25 mg, 50 mg, 100 mg, 200 mg and 300 mg are available as unit-of-use bottles of 30s.

The Lamictal XR brand and generic had combined U.S. sales of about $300.5 million for the 12 months ended in April, according to IMS Health data cited by Dr. Reddy's.

Lamotrigine is indicated for the treatment of epileptic seizures in adults and children. The drug also is used in the treatment of adults with bipolar disorder.

Advertisement